(2) Targeted therapy strategy: Monoclonal antibodies, small-molecule inhibitors, and other drugs targeting IL15 or its receptors can be developed to block the binding of IL15 to its receptors or inhibit its downstream signaling pathways, thereby interfering with the proliferation and survival of tumor cells. Here, IL15 is linked to neoplasm.